VI-0810 is under clinical development by Vivus and currently in Phase II for Diabetes. According to GlobalData, Phase II drugs for Diabetes have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VI-0810’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VI-0810 overview
VI-0810 is under development for the treatment of diabetes.
Vivus overview
Vivus, a subsidiary of Icahn Enterprises LP, is developing drugs for the treatment of exocrine pancreatic insufficiency, obesity and pulmonary arterial hypertension. The company is headquartered in Campbell, California, the US.
For a complete picture of VI-0810’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.